MedTrace Logo

Pharmacokinetic Study of Intravitreal Aflibercept Injection in Eyes With Wet Age-related Macular Degeneration

NCT02204683 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2023-09-06

No results posted yet for this study

Summary

The main goal is to study way that aflibercept injection behaves in the eye and in the body of patients with wet macular degeneration, in patients who have had previous vitreous removal surgery.

Conditions

  • Neovascular Macular Degeneration

Interventions

DRUG

Aflibercept

Intravitreal aflibercept

Sponsors & Collaborators

Principal Investigators

  • Diana V Do, MD · University of Nebraska

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-05
Primary Completion
2016-12-14
Completion
2016-12-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02204683 on ClinicalTrials.gov